Company Overview
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Why Investors Should Care
Generates a return on equity of 118.8%, reflecting efficient use of shareholder capital.
Revenue has grown at a 141.4% CAGR over the past five years.
Trades at a P/E of 20.8, below the sector median of 24.8.
Maintains a net profit margin of 70.8%.
Carries low leverage with a debt-to-equity ratio of 0.31.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $720.13M (+98.0% YoY); net profit $-228.03M.
- Trailing 12 Months Year-on-year growth — revenue +114.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 141.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 141.43% |
| 1 Year: | 114.70% |
Stock Price Performance
| 1 Year: | +41.35% |
| 6 Months: | +12.58% |
| 3 Months: | +31.23% |
| 1 Month: | +5.75% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)64.35 · Neutral
P/E of 20.79 is below the sector median of 24.83 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 118.8%.
- Excellent profit margin of 70.8%.
- Compounding revenue at 141.4% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ASND Ascendis Pharma A/S R3KPHARMA | 270.09 | 20.79 | $17.72B | 0.00% | -58.44% | 118.78% | 141.43% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 100.95M | 158.04M | 213.63M | 247.50M | 246.60M |
| Cost of Revenue | - | 17.52M | 31.45M | 22.35M | 23.60M | 17.52M |
| Gross Profit | - | 83.44M | 126.60M | 191.28M | 223.90M | 229.09M |
| Operating Expenses | - | 187.65M | 179.55M | 180.28M | 217.46M | 204.27M |
| Operating Income | - | -104.21M | -52.95M | 11.00M | 6.44M | 24.81M |
| EBITDA | - | -44.23M | 2.32M | -33.63M | -1.34M | 23.30M |
| Interest Expense | - | 44.79M | 33.02M | 19.72M | 20.54M | 67.25M |
| Pretax Income | - | -93.56M | -35.01M | -57.37M | -26.70M | -48.18M |
| Tax Provision | - | 1.06M | 3.85M | 3.62M | 6.86M | -677.52M |
| Net Income | - | -94.63M | -38.85M | -60.99M | -33.56M | 629.34M |
| Diluted EPS | - | -1.58 | -0.82 | -1.00 | -0.55 | 9.75 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 51.17M | 266.72M | 363.64M | 720.13M |
| Cost of Revenue | 12.14M | 44.40M | 44.26M | 94.92M |
| Gross Profit | 39.04M | 222.32M | 319.38M | 625.22M |
| Operating Expenses | 600.85M | 677.86M | 598.15M | 761.49M |
| Operating Income | -561.81M | -455.54M | -278.76M | -136.27M |
| EBITDA | -529.18M | -411.17M | -290.02M | -114.31M |
| Interest Expense | 30.68M | 44.06M | 65.50M | 80.65M |
| Pretax Income | -577.82M | -474.14M | -373.24M | -212.65M |
| Tax Provision | 5.38M | 7.30M | 4.84M | 15.38M |
| Net Income | -583.19M | -481.45M | -378.08M | -228.03M |
| Diluted EPS | -10.40 | -8.55 | -6.53 | -3.76 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 1.09B | 825.59M | 1.18B | 1.30B |
| Current Assets | - | 923.47M | 702.72M | 1.06B | 1.11B |
| Cash & Equivalents | - | 444.77M | 392.16M | 559.54M | 616.04M |
| Inventory | - | 130.67M | 208.93M | 295.61M | 301.53M |
| Receivables | - | 11.91M | 35.87M | 166.28M | 141.33M |
| Total Liabilities | - | 826.39M | 971.28M | 1.29B | 1.47B |
| Current Liabilities | - | 716.78M | 736.51M | 907.86M | 1.07B |
| Long Term Debt | - | 95.40M | 223.00M | 365.08M | 385.25M |
| Total Debt | - | 508.38M | 644.26M | 856.62M | 871.79M |
| Total Equity | - | 263.35M | -145.70M | -105.71M | -162.82M |
| Shares Outstanding | - | 58.27M | 57.71M | 60.69M | 61.98M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -495.70M | -467.36M | -306.20M | 53.90M |
| Investing Cash Flow | - | 61.73M | 286.47M | 6.88M | -8.48M |
| Financing Cash Flow | - | 396.77M | 134.29M | 443.93M | 36.33M |
| Capital Expenditure | - | -14.49M | -2.44M | -1.43M | -8.48M |
| Free Cash Flow | - | -510.19M | -469.80M | -307.62M | 45.41M |
| Net Change in Cash | - | -37.19M | -46.59M | 144.61M | 81.74M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | 76.3% | 83.4% | 87.8% | 86.8% |
| Operating Margin % | -1,097.9% | -170.8% | -76.7% | -18.9% |
| Net Margin % | -1,139.6% | -180.5% | -104.0% | -31.7% |
| ROE % | -221.5% | 330.4% | 357.7% | 140.1% |
| ROCE % | -150.6% | -511.4% | -102.6% | -58.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Massachusetts Financial Services Co. | - | 1.88M | $443.92M |
| 2 | Blackrock Inc. | - | 2.21M | $523.59M |
| 3 | Westfield Capital Management Co LP | - | 4.80M | $1.14B |
| 4 | Capital International Investors | - | 1.99M | $470.74M |
| 5 | FMR, LLC | - | 3.55M | $839.31M |
| 6 | Artisan Partners Limited Partnership | - | 2.63M | $623.53M |
| 7 | RA Capital Management, L.P. | - | 10.28M | $2.43B |
| 8 | T. Rowe Price Investment Management, Inc. | - | 6.75M | $1.60B |
| 9 | Avoro Capital Advisors LLC | - | 5.11M | $1.21B |
| 10 | Jupiter Topco LLC | - | 3.65M | $863.74M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ASND
Why Stocks Are Defying Gravity and What Could Bring Them Down - The New York Times
<a href="https://news.google.com/rss/articles/CBMiggFBVV95cUxPeVhZcEJvZ3BfMlcxazNWZFlTdUdaN0RZUk16aGh4TndmTTRFMnVrejJnbHA3eTRONzRrOXNlZ2ZrRG1sQlB0dFJqMlVPNzRNVG1PT0RvaDF4bGM0WFhrR2U5dS16VWlnNlUtb2tpWXhHdGVmTW1VdGJWR3dGVFlja0ln?oc=5" target=…
Stock Market Today: Stock Market News And Analysis - Investor's Business Daily
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE8zdGl1MmxTM2JJa2pLNlFSWVhuZUd1ekRIeVpDcGVqckVJcloxaWlnRHJ3b0hqb291NXk4dlo0SmRQNlhDaGpubDh6ZWNTUHZiYVhjOVJINUxSYXE0NHRiNVE2OW51R2h4N1daaXRIdzVBR1UxT0g4?oc=5" target="_blank">Stock M…
Stock Market Under the Trump Administration: What is Driving Markets in 2026? - U.S. Bank
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxPcUowVHR1VXAzd0Zfamw1MkVSejFsRGo1bkdGdHhjNVBZVFdwU3VpcE5neGJOeWl6RmdQVkFsYlcxNEVTRGg3WHNYSGR1d1BpTjV4T2NqdWdER3ZtQ0RVbU40WTcyRXRaTEM5bFZteVlYNE5EYkM1M1BaR0lYTGlUeFlTeDhVMzRaWFFqZE…
First trial data in babies with a rare growth condition will be shared this week - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxQbkdXd3JQN1BkRjVZeG5sRWsyeHFwZDk1Z3NYVEtCZ25nWXdDeVJ3azhfbjJmdnl4Nk43ZldKeTFoNUpvZm5mMndvekxVQjdtUWlzY2Jqa0JFNHhvY1B1dGJMeTRlellwWExYNGZuN1ZUOFc2S1VBTEpGakZpLTdNNTN6djl6bG5USGdpWm…
The markets establish a new pattern - Axios
<a href="https://news.google.com/rss/articles/CBMickFVX3lxTE81U1pla0FjbE9GS1FDWVdLcjV6ajZLZ0RpR2xOU01teFZiWlF0bm5BUWxvX2ppUXdTLUlrUkVzenFhT1E5Y2FRaVRUamY5R1NHZkxlSzkzWlJGd1EwM2psX2ZlOFJBU1ZTak13MkRVaS1OQQ?oc=5" target="_blank">The markets e…
Ascendis Pharma A/S (ASND) Stock Analysis: Unveiling a 16.35% Potential Upside for Investors - directorstalkinterviews.com
<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxOZ2c4VkFIa1BOSDducDVwZHBrOHRSM24yeElwckhjdEczNmNTazRmbVBialpwaWsweXZVMV9LMEZGV3Q3OE9aTWV3MWFIRUFRNzdMd05qQ3llWVZmVDFiNUxOTnktQXhUcEJPdjlFT010Wk0yNEJYSWUyMU1qZDhQeXozbUJ0UVlLVXA3cV…
ASND — Frequently Asked Questions
What is the current share price of Ascendis Pharma A/S (ASND)?
As of 2026-09-19 21:16 PDT, Ascendis Pharma A/S (ASND) trades at $270.09 on NasdaqGS. Its 52-week range is $189.74 to $277.18.
What is the market capitalisation of ASND?
Ascendis Pharma A/S (ASND) has a market capitalisation of $17.72B on NasdaqGS.
What is the P/E ratio of ASND?
ASND trades at a trailing price-to-earnings (P/E) ratio of 20.79. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 10.27.
What is the return on equity (ROE) of ASND?
ASND has a return on equity (ROE) of 118.78%. Its return on capital employed (ROCE) is -58.44%.
Is ASND a good stock to buy?
This page provides a data-driven analysis of Ascendis Pharma A/S (ASND), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.